Cure My Disease

Don't miss your cure!

 Log in / Sign up

New imaging agent aims to spot Hard-to-Find kidney cancer spread

NCT ID NCT07062549

Recruiting now Diagnosis Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Source: ClinicalTrials.gov ↗

First seen Jul 21, 2026 · Last updated Jul 22, 2026 · Updated 1 time

Summary

This early study tests whether a new radioactive tracer called 111In-XYIMSR-01 can help detect clear cell kidney cancer that has spread to other parts of the body. Six adults with confirmed metastatic clear cell renal cell carcinoma will receive the tracer and then undergo a SPECT/CT scan. The main goals are to check the tracer's safety and see how well it highlights cancer tissue.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
a radioactive tracer called 111In-XYIMSR-01
What this could lead to
If successful, this could lead to a more accurate way to detect metastatic clear cell kidney cancer using SPECT/CT scans.
What could go wrong
This is a very early, small study with only 6 participants, so results may not apply broadly. The tracer may not reliably detect tumors or could cause unexpected side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC CLEAR CELL RENAL CELL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

clear cell renal carcinoma kidney cancer renal cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RENAL CELL CARCINOMA (KIDNEY CANCER)

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Johns Hopkins University

    RECRUITING

    Baltimore, Maryland, 21287, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

More trials for these conditions

Other studies related to the condition(s) this trial covers.